Bicara Therapeutics Inc. Common Stock (BCAX) vs Integra LifeSciences Holdings Corporation (IART)

A side-by-side comparison of Bicara Therapeutics Inc. Common Stock and Integra LifeSciences Holdings Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Bicara Therapeutics Inc. Common Stock logo
BCAX
Bicara Therapeutics Inc. Common Stock
$1.12B
$17.05HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Integra LifeSciences Holdings Corporation logo
IART
Integra LifeSciences Holdings Corporation
$1.01B
$12.97HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT

Total return — BCAX vs IART

growth of $100 · dividends reinvested · last 2y
BCAX -26.1% (-14.1%/yr)IART -30.7% (-16.8%/yr)BCAX compounded faster over this window
406080100120140Start $10020252026$74$69
BCAX IART

BCAX vs IART: by the numbers

  • •BCAX is the larger company ($1.12B vs $1.01B market cap).
  • •Both run net losses; BCAX's is the smaller (0.00% vs -0.44% net margin).

Metrics side by side

Valuation

MetricBCAXIART
Forward P/EN/A5.32
P/S ratioN/A0.61
P/B ratio2.390.96
EV / EBITDAN/A3.50

Profitability

MetricBCAXIART
Gross margin0.00%53.74%
Operating margin0.00%4.18%
Net margin0.00%-0.44%
ROE-39.54%-0.69%
ROIC-42.98%20.01%

Growth (annualized)

MetricBCAXIART
Revenue CAGR (5Y)N/A1.77%
Total return CAGR (5Y)N/A-28.16%

Go deeper

Full BCAX analysisFull IART analysisInteractive comparison tool

Dig into the metrics

Bicara Therapeutics Inc. Common Stock ROEIntegra LifeSciences ROEBicara Therapeutics Inc. Common Stock operating marginIntegra LifeSciences operating marginBicara Therapeutics Inc. Common Stock revenue growthIntegra LifeSciences revenue growthBicara Therapeutics Inc. Common Stock free cash flowIntegra LifeSciences free cash flow

Bicara Therapeutics Inc. Common Stock & Integra LifeSciences appear in these rankings

Highest ROIC Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.